We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
Flexion Therapeutics, Inc. will provide updates on revenues from Zilretta and its other pipeline developments when it reports third-quarter 2021 results.
The company’s earnings history has been mixed so far with its bottom line beating estimates in two of the trailing four quarters and missing the same on the other two occasions, delivering an earnings beat of 0.68%, on average. In the last reported quarter, Flexion reported an earnings surprise of 12.00%.
Shares of Flexion have plunged 18.6% so far this year compared with the industry’s decrease of 16%.
Image Source: Zacks Investment Research
Let’s see how things are shaping up for the quarter to be reported.
Factors at Play
Flexion’s topline solely comprises sales of its only marketed drug Zilretta (triamcinolone acetonide extended-release injectable suspension). In the last reported quarter, revenues increased year over year, a trend that most likely continued in the third quarter as well.
Zilretta was approved in 2017 as the first and the only extended-release intra-articular therapy providing relief to osteoarthritis (OA) patients with knee pain.
This apart, Flexion is evaluating FX301 in a phase Ib study to address post-operative pain following bunionectomy surgery. The company is also investigating FX201, an intra-articular gene therapy candidate in an early-stage study for OA knee pain. Data from both studies are expected by 2021 end.
The activities related to the development of pipeline candidates are likely to have escalated operating expenses in the to-be-reported quarter.
In October 2021, Flexion entered into a definitive agreement with Pacira BioSciences (PCRX - Free Report) whereby the latter will acquire the former for $8.50 per share in cash plus one non-tradeable contingent value right worth up to $8 in cash. The transaction is expected to close later in the fourth quarter of 2021. We expect management to provide a thorough update on the same on the upcoming earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Flexion this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Flexion has an Earnings ESP of -4.13% as the Most Accurate Estimate currently stands at a loss of 55 cents per share while the Zacks Consensus Estimate is pegged at a loss of 53 cents.
Zacks Rank: Flexion has a Zacks Rank #4 (Sell), currently.
Here are a few stocks you may want to consider as our model shows that these have the right combination of elements to beat on earnings this reporting cycle:
Image: Bigstock
Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?
Flexion Therapeutics, Inc. will provide updates on revenues from Zilretta and its other pipeline developments when it reports third-quarter 2021 results.
The company’s earnings history has been mixed so far with its bottom line beating estimates in two of the trailing four quarters and missing the same on the other two occasions, delivering an earnings beat of 0.68%, on average. In the last reported quarter, Flexion reported an earnings surprise of 12.00%.
Shares of Flexion have plunged 18.6% so far this year compared with the industry’s decrease of 16%.
Let’s see how things are shaping up for the quarter to be reported.
Factors at Play
Flexion’s topline solely comprises sales of its only marketed drug Zilretta (triamcinolone acetonide extended-release injectable suspension). In the last reported quarter, revenues increased year over year, a trend that most likely continued in the third quarter as well.
Zilretta was approved in 2017 as the first and the only extended-release intra-articular therapy providing relief to osteoarthritis (OA) patients with knee pain.
This apart, Flexion is evaluating FX301 in a phase Ib study to address post-operative pain following bunionectomy surgery. The company is also investigating FX201, an intra-articular gene therapy candidate in an early-stage study for OA knee pain. Data from both studies are expected by 2021 end.
The activities related to the development of pipeline candidates are likely to have escalated operating expenses in the to-be-reported quarter.
In October 2021, Flexion entered into a definitive agreement with Pacira BioSciences (PCRX - Free Report) whereby the latter will acquire the former for $8.50 per share in cash plus one non-tradeable contingent value right worth up to $8 in cash. The transaction is expected to close later in the fourth quarter of 2021. We expect management to provide a thorough update on the same on the upcoming earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Flexion this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Flexion has an Earnings ESP of -4.13% as the Most Accurate Estimate currently stands at a loss of 55 cents per share while the Zacks Consensus Estimate is pegged at a loss of 53 cents.
Zacks Rank: Flexion has a Zacks Rank #4 (Sell), currently.
Flexion Therapeutics, Inc. Price and EPS Surprise
Flexion Therapeutics, Inc. price-eps-surprise | Flexion Therapeutics, Inc. Quote
Stocks to Consider
Here are a few stocks you may want to consider as our model shows that these have the right combination of elements to beat on earnings this reporting cycle:
Gemini Therapeutics, Inc. has an Earnings ESP of +17.61 % and a Zacks Rank #2, currently. You can see the complete list of today’s Zacks #1 Rank stocks here.
Ardelyx, Inc. (ARDX - Free Report) has an Earnings ESP of +2.22% and a Zacks Rank #3 at present.